Figure 3.
Geometric mean percentage (±95% confidence intervals) changes from baseline in (A) proprotein convertase subtilisin kexin type 9 (PCSK9) and (B) ultracentrifugation (UC) low‐density lipoprotein cholesterol (LDL‐C) by degree of hepatic impairment.